Autolus Therapeutics
AUTL
38 hedge funds and large institutions have $558M invested in Autolus Therapeutics in 2018 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 6 increasing their positions, 18 reducing their positions, and 12 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
2% more capital invested
Capital invested by funds: $546M → $558M (+$11.6M)
8% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 12
3% less funds holding
Funds holding: 39 → 38 (-1)
3.71% less ownership
Funds ownership: 46.02% → 42.31% (-3.7%)
67% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 18
Top Buyers
Top Sellers
AUTL Hedge Fund Activity: Q4 2018 in Review
38 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q4 2018, worth a combined $558M — up 2.1% from $546M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of AUTL and 11 opened new positions — a net loss of 1 holder — while 18 trimmed existing stakes and 6 added.
The largest buyer was Woodford Investment Management, adding an estimated $36.2M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $40.7M sold.
- 38 institutional investors held Autolus Therapeutics (AUTL) as of Q4 2018, down from 39 in Q3 2018.
- Funds reported $558M of Autolus Therapeutics stock for Q4 2018, up 2.1% quarter-over-quarter.
- 11 funds opened new Autolus Therapeutics positions in Q4 2018 and 12 closed out, a net change of -1 holder.
- The largest Autolus Therapeutics buyer in Q4 2018 was Woodford Investment Management, an estimated $36.2M added.
- The largest Autolus Therapeutics seller in Q4 2018 was Cormorant Asset Management, an estimated $40.7M sold.
Based on aggregated 13F filings for Q4 2018.